Clinical Study

Analysis of Safety from a Human Clinical Trial with Pterostilbene

Table 1

Baseline Demographics.

High doseLow doseLow dose + grape extractPlacebo

Age (years)54545354
Gender (%) (M/F) 30/7025/7525/7535/65
Race (%) (CA/AA/Asian)80/20/075/25/075/15/1050/50/0
Smokers (%)1515100
Concomitant disease (%)a60604070
Cholesterol medication use (%)b35353540
Framingham 10-year risk (%)6666

ā€‰aincludes hypertension (overall incidence: 55%), diabetes (5%), atherosclerotic cardiovascular disease (1%), or restrictive/obstructive airway disease (8%).
ā€‰b>75% of the cholesterol medication used in any group were statins.